Oracle Unveils New Version of Oracle Health Sciences ClearTrial Plan and Source Cloud Service
Cloud-Based Clinical Trial Operations Software Delivers Enhanced Planning, Sourcing, and Tracking Capabilities to Support Phase I Trials and Complex Multi-Arm Studies
Oracle Health Sciences today announced the availability of Oracle Health Sciences ClearTrial Plan and Source Cloud Service 5.0, the latest version of the cloud-based clinical trial operations solution that enables life sciences organizations to plan, source and track clinical projects and financial performance via a single, integrated platform.
The newest release now provides support for phase I trials, which when combined with existing capabilities, enables organizations to support a broad range of clinical trials – from initial safety screenings to complex testing and post-approval studies – in one scalable and flexible solution.
Further expanding the breadth and study types that sponsors and contract research organizations (CROs) can create and track, the latest release also provides support for multiple treatment arm studies – including complex cross over studies, in which different types and sequences of treatment courses are administered to various study groups.
Oracle Health Sciences ClearTrial Plan and Source is now delivered via the Oracle Health Sciences Cloud, providing users with improved performance, availability and fault tolerance. In addition, as a cloud-based solution, users will gain immediate access to ClearTrial’s enhanced functionality and improved user interface.
“We remain committed to evolving the breadth and depth of Oracle ClearTrial Plan and Source Cloud Service’s capabilities to provide life sciences organizations with the tools they need to conduct and track increasingly complex clinical trials across diverse geographies, outsourcers, therapeutic areas and trial phases,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “The new capabilities will allow life sciences organizations to gain a competitive edge in the marketplace while accelerating the process of bringing new therapies to market.”
Related Links
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
